Carina Liane Hutz
Rheumatologie · Dept. I
Novartis_CLNA043A12203
Dec 30, 2022A randomized, four-arm, canakinumab placebo-controlled, participant, investigator and sponsor-blinded study investigating the safety, tolerability and efficacy of intra-articular canakinumab followed by intra-articular LNA043 in patients with knee os...
Clinical Studies - Dec 30, 2022 - Dec 31, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Peischl Shirin, Bartz-Batliner Mira, Peischl Riana, Hutz Carina Liane
Horizon_HZNP-HZN-825-301
Nov 30, 2022A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
Clinical Studies - Nov 30, 2022 - Dec 31, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Peischl Shirin, Peischl Riana, Bartz-Batliner Mira, Hutz Carina Liane
Athena-SSc-ILD-Study
Aug 23, 2022A double blind, randomized, placebo-controlled study to evaluate the efficacy and safety of PRA023 in Subject with Systemic Sclerosis associated with interstitial Lung Disease.
Clinical Studies - Aug 23, 2022 - Aug 23, 2024
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Peischl Riana, Peischl Shirin, Bartz-Batliner Mira, Hutz Carina Liane, Schmiedeberg Kristin
BMS_IM101-863
Jan 24, 2022A Phase 3, Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA...
Clinical Studies - Jan 24, 2022 - Jan 17, 2025
Completed
Project leader: Rubbert-Roth Andrea
Members: Peischl Shirin, Peischl Riana, Bartz-Batliner Mira, Haller Christoph, Pirker Ian, Hutz Carina Liane
AbbVie UPSTAND P20-410 SLEESPA
Dec 10, 2021Real World Effectiveness of Upadacitinib on Early and Sustained Pain Control and Sleep Quality in Radiographic Axial Spondyloarthritis
Clinical Studies - Dec 10, 2021 - Dec 10, 2024
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Peischl Shirin, Peischl Riana, Hutz Carina Liane
RECOVER: Rheumatoid Covid-19 Vaccine Immune Response
Feb 1, 2021Untersuchung der Sicherheit und Effektivität von mRNA basierten COVID-19 Impfungen bei Patienten mit rheumatoider Arthritis - ein exploratives Forschungsprojekt
Clinical Studies - Feb 1, 2021 - Dec 31, 2022
Completed
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Riana, Peischl Shirin, Sasselli Clelia, Hutz Carina Liane
Abbvie UPHOLD P20-095 SLEERA
Aug 1, 2020Upadacitinib treatment patterns, achievement of treatment targets and maintenance of response in moderate to severe Rheumatoid Arthritis patients in real-world practice
Clinical Studies - Aug 1, 2020 - Oct 31, 2023
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Peischl Shirin, Schmiedeberg Kristin
CAIN457Q12301
Jul 13, 2020A two-year, phase III randomized, double-blind, parallel- group, placebo- controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo in combination with SoC therapy in patients with active lupus neph...
Clinical Studies - Jul 13, 2020 - Jul 12, 2023
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Sasselli Clelia
IgPro20_3007: RECLAIM
Feb 5, 2020A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
Clinical Studies - Feb 5, 2020 - Dec 30, 2025
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Peischl Riana, Sasselli Clelia
Abbvie M16-852 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and
Apr 2, 2019Giant Cell Arteritis: Phase 3 Safety and Efficacy Study of Upadacitinib in Subjects with Giant Cell Arteritis
Clinical Studies - Apr 2, 2019 - Dec 31, 2024
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Neumann Thomas, Peischl Riana, Sasselli Clelia
Lilly JAHZ A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib
Feb 28, 2019A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with systemic lupus erythematosus (SLE).
Clinical Studies - Feb 28, 2019 - Feb 28, 2022
Completed
Project leader: Rubbert-Roth Andrea
Members: Neumann Thomas, Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Sasselli Clelia
CORBUS: Lenabasum bei diffuser systemischer Sklerose
Sep 25, 2018A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Clinical Studies - Sep 25, 2018 - Sep 27, 2021
Aborted
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Neumann Thomas
Abbvie M15-925: A Phase 3, Randomized, Active-Controlled,
Aug 15, 2018
Clinical Studies - Aug 15, 2018 - Aug 16, 2024
Completed
Project leader: Hutz Carina Liane, Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Neumann Thomas
Skippain
Jan 29, 2018SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with AxIal SpoNdyloarthritis) A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of secukinumab in controlling sp...
Clinical Studies - Jan 29, 2018 - Jun 29, 2019
Completed
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Forrer Silvia, Bartz-Batliner Mira
Lilly RHCF SPIRIT
Oct 16, 2017A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
Clinical Studies - Oct 16, 2017 - Oct 24, 2021
Completed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Forrer Silvia, Hutz Carina Liane, Neumann Thomas
Abbvie M15-572 Phase 3 PsA mit inadäquater Response auf bDMARD
Oct 2, 2017A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumat...
Clinical Studies - Oct 2, 2017 - Oct 3, 2024
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Neumann Thomas
Finch 302 Gilead
May 24, 2017A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Sub...
Clinical Studies - May 24, 2017 - Sep 26, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Schmidig Kathrin
CCX_Chemocentryx CL010 CCX168 (Avacopan)
May 15, 2017A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cycloph...
Clinical Studies - May 15, 2017 - May 31, 2021
Completed
Project leader: Neumann Thomas
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Rubbert-Roth Andrea
BIOBIO
Feb 14, 2017A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action
Clinical Studies - Feb 14, 2017 - Aug 16, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Schmidig Kathrin
Maximise
Dec 5, 2016MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52-week study to assess the efficacy and safety of secukinumab 150 mg or 300 mg s.c. in patients with activ...
Clinical Studies - Dec 5, 2016 - Sep 13, 2019
Completed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Forrer Silvia